Most molecules die in early discovery for one of two reasons.
Either the chemistry never worked well enough to advance. Or it worked, but the wrong problems were left unaddressed for too long.
Both failure modes are preventable. The choice of strategy at the lead stage determines which problems you catch and how fast.
Scaffold hopping and lead optimization are the two core medicinal chemistry approaches at this stage. They are not interchangeable. Knowing when to use which one separates programs that reach IND from those that stall at hit-to-lead.
What Lead Optimization Actually Does
Lead optimization in drug discovery starts with a confirmed hit and improves it systematically.
The core scaffold stays intact. The work focuses on decorating it — adjusting substituents, modifying functional groups, and building SAR to understand what drives potency, selectivity, and drug-like behavior.
Key techniques include:
• Bioisosteric replacement: swapping a functional group for a chemically similar one to improve pharmacokinetics or reduce toxicity while keeping biological activity intact
• Conformational constraint: locking a flexible molecule into its bioactive conformation to improve potency and selectivity
• SAR optimization: iterative synthesis and testing to map which parts of the molecule drive activity and which introduce liabilities
• Property-based design: balancing potency with ADMET properties from the start, not optimizing one and fixing the other later
The risk in lead optimization is momentum. When SAR is progressing, teams can push further along the same scaffold without noticing that a fundamental liability lives in the core structure itself.
That is when molecular weight creeps up, lipophilicity rises, and ADMET properties deteriorate. Researchers call this “molecular obesity” and recognize it as a direct contributor to high drug discovery attrition rates.
What Scaffold Hopping Medicinal Chemistry Does Differently
Scaffold hopping replaces the core structure entirely.
The pharmacophore — the arrangement of atoms responsible for binding — is preserved, but the molecular framework holding it is changed.
The term was coined by Schneider and colleagues in 1999 and is now a standard strategy for programs facing specific blockers:
• The current scaffold is locked in by a competitor’s patent
• The core structure is metabolically labile and cannot be fixed through peripheral modifications
• Off-target toxicity traces back to the scaffold itself, not the substituents
• Selectivity issues require a structurally distinct binding mode
• Physical properties limit formulation options at current molecular weight
Published examples show the impact. Scaffold hopping contributed to Nirmatrelvir, Sorafenib, Bosutinib, and Vadadustat — cases where a core change unlocked properties that substituent-level work could not achieve.
A fragment-hopping study on PIM-1 kinase inhibitors showed replacing the scaffold improved metabolic stability in human liver microsomes by over 45% and off-target selectivity by more than two log units, while keeping primary activity in the 20 to 150 nM range.
The Decision Point: Which Strategy to Use When
The choice is not always obvious. The trigger for scaffold hopping medicinal chemistry is specific.
Use lead optimization when:
• The scaffold has a clean IP position and no core liability
• SAR is rich and room exists to improve properties through substitution
• ADMET issues can be addressed by modifying peripheral groups
Switch to or add scaffold hopping when:
• A core structural alert is generating metabolic or toxicity risk that peripheral changes cannot resolve
• The IP landscape requires a structurally novel series
• Selectivity issues trace to scaffold geometry, not substituents
• The molecule is approaching rule-of-five limits and further decoration will worsen properties
Running both strategies in parallel during lead generation is sometimes the right call. It builds a backup series and expands the candidate pool before committing to one scaffold family.
How LAXAI’s Medicinal Chemistry Team Navigates This
LAXAI’s medicinal chemistry team works across both lead optimization and scaffold hopping within integrated discovery programs.
The team conducts SAR optimization alongside in vitro biology and DMPK studies in-house. ADMET data feeds directly into design cycles without waiting for external lab results.
When a scaffold shows core liabilities, LAXAI’s synthetic chemists move to scaffold exploration early — before significant resources are spent advancing a chemotype that cannot be fixed downstream.
That integration — chemistry, biology, DMPK, and safety under one roof — allows faster decision-making at the lead-generation stage and a cleaner candidate profile with lower late-stage drug discovery attrition.
Speak to LAXAI’s medicinal chemistry team at bd@laxai.com
FAQs
What is scaffold hopping in medicinal chemistry?
Scaffold hopping replaces the core molecular framework of a lead compound while retaining the pharmacophore responsible for biological activity. It is used when the existing scaffold has IP constraints, metabolic liabilities, or selectivity problems that peripheral modifications cannot resolve.
How is scaffold hopping different from lead optimization?
Lead optimization works within the existing core structure through substituent changes and functional group modifications. Scaffold hopping changes the core itself. Both strategies aim to improve ADMET properties and reduce attrition, but scaffold hopping carries greater structural change and synthetic complexity.
When should a medicinal chemistry team consider scaffold hopping?
When the scaffold carries a core liability — metabolic instability, toxicity, poor selectivity, or IP conflict — that cannot be fixed through substitution alone. The decision is typically driven by DMPK and in vitro safety data.
Does LAXAI support scaffold hopping programs?
Yes. LAXAI runs integrated discovery programs covering both strategies, with in-house medicinal chemistry, biology, and DMPK capabilities supporting faster design-make-test cycles.
